Last reviewed · How we verify
NCT05488990: AKVANO-AKP01
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
Phase 1, PHASE2 trial testing AKVANO-Calcipotriol formulation 1 in Psoriasis Vulgaris in 24 participants. Completed in 17 June 2013.
17 June 2013
Quick facts
| Lead sponsor | Lipidor AB |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 25 March 2013 |
| Primary completion | 17 June 2013 |
| Estimated completion | 17 June 2013 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- AKVANO-Calcipotriol formulation 1 — full drug profile →
- AKVANO-Calcipotriol formulation 2 — full drug profile →
- AKVANO vehicle formulation 1 — full drug profile →
- AKVANO vehicle formulation 2 — full drug profile →
- Daivonex solution — full drug profile →
- Daivonex cream
Conditions studied
- Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
Sponsor
Lipidor AB — full company profile →
Who can join
Adults 32 to 69, any sex, with Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex® solution and cream) and to evaluate their cutaneous safety in a psoriasis plaque test
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05488990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis Vulgaris
Currently open trials in the same condition.
- NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
- NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
- NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
- NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
- NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting
Other Lipidor AB trials
Trials by the same sponsor.
- NCT05249972 — A Phase III Study in Subjects With Mild to Moderate Psoriasis. · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05488990 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lipidor AB
- Last refreshed: 5 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05488990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing